Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2 HKD | +3.09% | +6.95% | +11.11% |
Valuation
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 259.4 | 143.3 | 63.15 | 81.33 | 86.49 | 101.2 |
Enterprise Value (EV) 1 | 239.4 | 127.5 | 33.85 | 57.42 | 89.68 | 106.7 |
P/E ratio | 102 x | -26 x | -19.4 x | 90.6 x | 22.1 x | -34 x |
Yield | 0.28% | - | - | - | - | - |
Capitalization / Revenue | 4.49 x | 2.79 x | 1.31 x | 1.95 x | 1.76 x | 2.2 x |
EV / Revenue | 4.14 x | 2.48 x | 0.7 x | 1.38 x | 1.82 x | 2.32 x |
EV / EBITDA | 31.8 x | -53.7 x | -15.2 x | -471 x | 15.4 x | -2,668 x |
EV / FCF | 16.6 x | -2.72 x | 0.61 x | 17.1 x | 52.7 x | -94.2 x |
FCF Yield | 6.01% | -36.7% | 163% | 5.85% | 1.9% | -1.06% |
Price to Book | 4.28 x | 2.47 x | 1.78 x | 3.47 x | 4.96 x | 6.99 x |
Nbr of stocks (in thousands) | 480,400 | 485,736 | 485,736 | 396,736 | 396,736 | 396,736 |
Reference price 2 | 0.5400 | 0.2950 | 0.1300 | 0.2050 | 0.2180 | 0.2550 |
Announcement Date | 6/21/18 | 6/27/19 | 6/29/20 | 6/21/21 | 6/20/22 | 6/21/23 |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 57.79 | 51.45 | 48.05 | 41.71 | 49.15 | 46.02 |
EBITDA 1 | 7.525 | -2.373 | -2.226 | -0.122 | 5.806 | -0.04 |
EBIT 1 | 3.349 | -6.965 | -5.045 | -2.312 | 3.638 | -2.257 |
Operating Margin | 5.79% | -13.54% | -10.5% | -5.54% | 7.4% | -4.9% |
Earnings before Tax (EBT) 1 | 3.528 | -8.727 | -5.313 | 1.314 | 4.421 | -3.031 |
Net income 1 | 2.533 | -5.48 | -3.237 | 0.953 | 3.922 | -2.976 |
Net margin | 4.38% | -10.65% | -6.74% | 2.28% | 7.98% | -6.47% |
EPS 2 | 0.005272 | -0.0113 | -0.006699 | 0.002262 | 0.009885 | -0.007501 |
Free Cash Flow 1 | 14.39 | -46.8 | 55.15 | 3.361 | 1.702 | -1.134 |
FCF margin | 24.9% | -90.97% | 114.79% | 8.06% | 3.46% | -2.46% |
FCF Conversion (EBITDA) | 191.23% | - | - | - | 29.32% | - |
FCF Conversion (Net income) | 568.11% | - | - | 352.69% | 43.4% | - |
Dividend per Share 2 | 0.001500 | - | - | - | - | - |
Announcement Date | 6/21/18 | 6/27/19 | 6/29/20 | 6/21/21 | 6/20/22 | 6/21/23 |
Balance Sheet Analysis
Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 3.19 | 5.55 |
Net Cash position 1 | 20 | 15.8 | 29.3 | 23.9 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | 0.5498 x | -138.8 x |
Free Cash Flow 1 | 14.4 | -46.8 | 55.2 | 3.36 | 1.7 | -1.13 |
ROE (net income / shareholders' equity) | 3.18% | -15.3% | -12.6% | 5.41% | 24.3% | -23.9% |
ROA (Net income/ Total Assets) | 2.31% | -5.17% | -3.79% | -2.11% | 3.94% | -2.74% |
Assets 1 | 109.7 | 105.9 | 85.34 | -45.11 | 99.62 | 108.7 |
Book Value Per Share 2 | 0.1300 | 0.1200 | 0.0700 | 0.0600 | 0.0400 | 0.0400 |
Cash Flow per Share 2 | 0.0400 | 0.0300 | 0.0900 | 0.0700 | 0.0400 | 0.0100 |
Capex 1 | 0.66 | 3.98 | 1.7 | 2.31 | 1.97 | 2.3 |
Capex / Sales | 1.14% | 7.73% | 3.54% | 5.53% | 4% | 5% |
Announcement Date | 6/21/18 | 6/27/19 | 6/29/20 | 6/21/21 | 6/20/22 | 6/21/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.11% | 9.85M | |
-14.72% | 564M | |
+42.60% | 495M | |
-26.06% | 396M | |
+0.86% | 272M | |
-18.97% | 212M | |
-24.33% | 97.99M | |
-4.20% | 81.73M | |
-12.41% | 65.03M | |
-24.69% | 62.01M |
- Stock Market
- Equities
- 8307 Stock
- Financials Medicskin Holdings Limited